NCT04278781

AG-120 in People With IDH1 Mutant Chondrosarcoma

Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

Conditions

• Chondrosarcoma
• Chondrosarcoma, Grade 2
• Chondrosarcoma, Grade 3
• IDH1 Gene Mutation

Interventions

Type	Name	Description
DRUG	AG-120	AG-120 500 mg orally once daily days 1-28 of a 28-day cycle

Timeline

• Start date: 2020-03-04
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2020-02-20
• Last updated: 2025-10-23

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study